95 related articles for article (PubMed ID: 1794373)
1. In vitro activity of the new glycopeptide LY264826 versus vancomycin against clinical isolates of enterococci.
Watanakunakorn C
Eur J Clin Microbiol Infect Dis; 1991 Nov; 10(11):982-3. PubMed ID: 1794373
[No Abstract] [Full Text] [Related]
2. Comparison of LY264826-gentamicin with vancomycin-gentamicin against enterococci from blood cultures.
Watanakunakorn C
J Antimicrob Chemother; 1992 Mar; 29(3):303-6. PubMed ID: 1592699
[TBL] [Abstract][Full Text] [Related]
3. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.
Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Stratford RE; Cooper RD
Antimicrob Agents Chemother; 1995 Nov; 39(11):2585-7. PubMed ID: 8585753
[TBL] [Abstract][Full Text] [Related]
4. The in-vitro activity of LY333328, a new glycopeptide, against clinical isolates of vancomycin-resistant enterococci.
Kirk M; Hill RL; Casewell MW; Beighton D
Adv Exp Med Biol; 1997; 418():483-5. PubMed ID: 9331699
[No Abstract] [Full Text] [Related]
5. Resistance of enterococci to ampicillin and glycopeptide antibiotics in Italy. The Italian Surveillance Group for Antimicrobial Resistance.
Fontana R; Ligozzi M; Mazzariol A; Veneri G; Cornaglia G
Clin Infect Dis; 1998 Aug; 27 Suppl 1():S84-6. PubMed ID: 9710675
[TBL] [Abstract][Full Text] [Related]
6. Occurrence of vancomycin-resistant enterococci in relation to the administration of glycopeptide antibiotics.
Kolár M; Vágnerová I; Látal T; Kohnová I
Acta Univ Palacki Olomuc Fac Med; 1999; 142():69-71. PubMed ID: 10743728
[TBL] [Abstract][Full Text] [Related]
7. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
Fraise AP; Andrews J; Wise R
J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
[TBL] [Abstract][Full Text] [Related]
8. Hybrid glycopeptide antibiotics.
Sun B; Chen Z; Eggert US; Shaw SJ; LaTour JV; Kahne D
J Am Chem Soc; 2001 Dec; 123(50):12722-3. PubMed ID: 11741455
[No Abstract] [Full Text] [Related]
9. The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin-susceptible and vancomycin-resistant enterococci.
Itokazu GS; Nathan C; Hariharan R; Kostman JR; Kabins SA; Weinstein RA
Chemotherapy; 1996; 42(4):235-9. PubMed ID: 8804789
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
Barber KE; Smith JR; Raut A; Rybak MJ
J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
[TBL] [Abstract][Full Text] [Related]
11. Importance of the structure of vancomycin binding pocket in designing compounds active against vancomycin-resistant enterococci (VRE).
Jia Y; Bois-Choussy M; Malabarba A; Brunati C; Zhu J
J Antibiot (Tokyo); 2006 Sep; 59(9):543-52. PubMed ID: 17136887
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibilities of clinical isolates of vancomycin-resistant enterococci.
Evans PA; Norden CW; Rhoads S; Deobaldia J; Silber JL
Antimicrob Agents Chemother; 1997 Jun; 41(6):1406. PubMed ID: 9174211
[No Abstract] [Full Text] [Related]
13. Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci.
Neudorfer K; Schmidt-Malan SM; Patel R
Diagn Microbiol Infect Dis; 2018 Jan; 90(1):58-63. PubMed ID: 29195766
[TBL] [Abstract][Full Text] [Related]
14. [Vancomycin resistant enterococci in Austria].
Allerberger F; Lass-Flörl C; Dierich MP; Hirschl AM; Presterl E; Haas G; Klare I; Witte W
Wien Klin Wochenschr; 1997 May; 109(9):312-20. PubMed ID: 9265389
[TBL] [Abstract][Full Text] [Related]
15. In-vitro study of the synergy between beta-lactam antibiotics and glycopeptides against enterococci.
Ravizzola G; Cabibbo E; Peroni L; Longo M; Pollara PC; Corulli M; Pizzi R; Dima F; Fallacara C; Turano A
J Antimicrob Chemother; 1997 Apr; 39(4):461-70. PubMed ID: 9145818
[TBL] [Abstract][Full Text] [Related]
16. Typing of Enterococcus spp. strains in 4 hospitals in the Małopolska region in Poland.
Talaga K; Odrowąż-Konduracka D; Paradowska B; Jagiencarz-Starzec B; Wolak Z; Bulanda M; Szczypta A
Adv Clin Exp Med; 2018 Jan; 27(1):111-117. PubMed ID: 29521051
[TBL] [Abstract][Full Text] [Related]
17. Vancomycin-resistant enterococci in Brooklyn, New York: a moment in time.
Landman D; Volkert F; Manikal V; Saurina G; Ruan Y; Oydna E; Parola C; Quale J
Clin Infect Dis; 1999 Dec; 29(6):1587-8. PubMed ID: 10585828
[No Abstract] [Full Text] [Related]
18. In vitro activity of daptomycin against isolates of Staphylococcus aureus and enterococci: first results from Turkey.
Arslan H; Azap OK; Ergin F; Karaman SO; Oruç E
Int J Antimicrob Agents; 2004 Jun; 23(6):642-3. PubMed ID: 15194140
[No Abstract] [Full Text] [Related]
19. Novel glycopeptide antibiotics: N-alkylated derivatives active against vancomycin-resistant enterococci.
Rodriguez MJ; Snyder NJ; Zweifel MJ; Wilkie SC; Stack DR; Cooper RD; Nicas TI; Mullen DL; Butler TF; Thompson RC
J Antibiot (Tokyo); 1998 Jun; 51(6):560-9. PubMed ID: 9711219
[TBL] [Abstract][Full Text] [Related]
20. In-vitro selection of resistance to vancomycin and teicoplanin in Enterococcus faecium and Enterococcus faecalis compared with Staphylococcus epidermidis.
Markopulos E; Graninger W; Georgopoulos A
J Antimicrob Chemother; 1998 Jan; 41(1):43-7. PubMed ID: 9511036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
